Patients suffering from acute coronary syndrome (ACS) present a high risk of recurrence and new adverse cardiovascular events after hospital discharge. Elevated plasma LDL-cholesterol (LDL-C) levels have been shown to be a causal factor for the development of coronary heart disease, and robust clinical evidence has documented that LDL-C levels decrease linearly correlates with a reduction in cardiovascular events. Recent studies have also demonstrated the safety and efficacy of an early and significant reduction in LDL-C levels in patients with ACS. In this position paper, Italian Association of Hospital Cardiologists proposes a decision algorithm on early adoption of lipid-lowering strategies at hospital discharge and short-term follow-up of patients with ACS, in the light of the multiple evidence generated in recent years on the treatment of hypercholesterolaemia and the available therapeutic options, considering current reimbursement criteria.
De Luca, L., Riccio, C., Navazio, A., Valente, S., Cipriani, M., Corda, M., et al. (2023). ANMCO position paper on the management of hypercholesterolaemia in patients with acute coronary syndrome. EUROPEAN HEART JOURNAL SUPPLEMENTS, 25(SD), D299-D309 [10.1093/eurheartjsupp/suad100].
ANMCO position paper on the management of hypercholesterolaemia in patients with acute coronary syndrome
Valente S.;
2023-01-01
Abstract
Patients suffering from acute coronary syndrome (ACS) present a high risk of recurrence and new adverse cardiovascular events after hospital discharge. Elevated plasma LDL-cholesterol (LDL-C) levels have been shown to be a causal factor for the development of coronary heart disease, and robust clinical evidence has documented that LDL-C levels decrease linearly correlates with a reduction in cardiovascular events. Recent studies have also demonstrated the safety and efficacy of an early and significant reduction in LDL-C levels in patients with ACS. In this position paper, Italian Association of Hospital Cardiologists proposes a decision algorithm on early adoption of lipid-lowering strategies at hospital discharge and short-term follow-up of patients with ACS, in the light of the multiple evidence generated in recent years on the treatment of hypercholesterolaemia and the available therapeutic options, considering current reimbursement criteria.File | Dimensione | Formato | |
---|---|---|---|
ANMCO position paper on the management of-Valente-2023.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
PDF editoriale
Licenza:
Creative commons
Dimensione
1.97 MB
Formato
Adobe PDF
|
1.97 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1280050